BlueMountain Capital Management LLC trimmed its stake in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 23.3% during the 2nd quarter, Holdings Channel reports. The fund owned 44,045 shares of the medical equipment provider’s stock after selling 13,369 shares during the quarter. BlueMountain Capital Management LLC’s holdings in Lantheus were worth $641,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of LNTH. Piedmont Investment Advisors LLC bought a new position in Lantheus during the 2nd quarter worth approximately $104,000. Itau Unibanco Holding S.A. bought a new position in Lantheus during the 2nd quarter worth approximately $104,000. NumerixS Investment Technologies Inc grew its position in Lantheus by 1,000.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 7,000 shares during the last quarter. Sun Life Financial INC bought a new position in Lantheus during the 2nd quarter worth approximately $140,000. Finally, SG Americas Securities LLC bought a new position in Lantheus during the 2nd quarter worth approximately $151,000. Institutional investors and hedge funds own 92.52% of the company’s stock.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Wells Fargo & Co reduced their price target on Lantheus from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 2nd. Credit Suisse Group cut their price objective on Lantheus from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Thursday, August 2nd. ValuEngine upgraded Lantheus from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Finally, Zacks Investment Research upgraded Lantheus from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Lantheus presently has a consensus rating of “Hold” and a consensus price target of $23.75.

In other news, Director Julie Mchugh sold 4,560 shares of Lantheus stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $14.72, for a total value of $67,123.20. Following the sale, the director now directly owns 14,752 shares in the company, valued at approximately $217,149.44. The sale was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Shares of LNTH stock opened at $16.15 on Wednesday. The company has a market capitalization of $626.20 million, a PE ratio of 16.23, a price-to-earnings-growth ratio of 3.76 and a beta of 1.30. Lantheus Holdings Inc has a fifty-two week low of $12.80 and a fifty-two week high of $24.45. The company has a debt-to-equity ratio of 5.94, a quick ratio of 3.14 and a current ratio of 3.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. The firm had revenue of $85.60 million for the quarter, compared to analyst estimates of $87.90 million. Lantheus had a return on equity of 560.19% and a net margin of 37.53%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the company earned $0.35 EPS. research analysts forecast that Lantheus Holdings Inc will post 0.87 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.